Affordable Access

deepdyve-link
Publisher Website

[KRAS status versus EGFR status in lung cancer therapy].

Authors
  • Lacroix, L
  • Besse, B
  • Bidart, J-M
  • Bosq, J
Type
Published Article
Journal
Bulletin du Cancer
Publisher
Elsevier
Publication Date
Dec 01, 2009
Volume
96 Suppl
Identifiers
DOI: 10.1684/bdc.2009.0999
PMID: 20034873
Source
Medline
License
Unknown

Abstract

Interest for development of molecular biomarkers tends to increase in clinical management of lung cancer. Indeed implementation in clinics of new molecules targeting epithelial growth factor (EGFR) such as erlotinib or gefitinib, rise several questions regarding the potential value of EGFR and KRAS mutations to predict therapeutic response. In the current review, we discuss the utilization of such biomarkers regarding published clinical data and the possibilities versus limitations associated with analyses performed in molecular laboratory on a daily setting basis.

Report this publication

Statistics

Seen <100 times